⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for prostate specific membrane antigen

Every month we try and update this database with for prostate specific membrane antigen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057NCT02916537
Prostate Cancer
CTT1057
Prostatectomy
18 Years - Cancer Targeted Technology
PSMA-PET Imaging of Salivary Gland Tumours and Other Rare CancersNCT05581979
Salivary Gland ...
Rare Malignant ...
68-Ga PSMA PET ...
21 Years - 99 YearsNational Cancer Centre, Singapore
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to ProstatectomyNCT04430192
Prostatic Neopl...
177Lu-PSMA-617
18 Years - Peter MacCallum Cancer Centre, Australia
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate CancerNCT05354375
Immunotherapy
CAR-T cell immu...
18 Years - 75 YearsThe Affiliated Hospital of Xuzhou Medical University
18F-PSMA PET/CT for Visualization of Glioblastoma MultiformeNCT04588454
Glioblastoma Mu...
18F-PSMA-1007 P...
18 Years - Radboud University Medical Center
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell CarcinomaNCT03427476
Renal Cell Carc...
CTT1057
18 Years - Cancer Targeted Technology
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate CancerNCT05354375
Immunotherapy
CAR-T cell immu...
18 Years - 75 YearsThe Affiliated Hospital of Xuzhou Medical University
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to ProstatectomyNCT04430192
Prostatic Neopl...
177Lu-PSMA-617
18 Years - Peter MacCallum Cancer Centre, Australia
ARX517 in Subjects With Metastatic Castration-Resistant Prostate CancerNCT04662580
Prostate Cancer
ARX517
18 Years - Ambrx, Inc.
PSMA-PET Imaging of Salivary Gland Tumours and Other Rare CancersNCT05581979
Salivary Gland ...
Rare Malignant ...
68-Ga PSMA PET ...
21 Years - 99 YearsNational Cancer Centre, Singapore
ARX517 in Subjects With Metastatic Castration-Resistant Prostate CancerNCT04662580
Prostate Cancer
ARX517
18 Years - Ambrx, Inc.
ARX517 in Subjects With Metastatic Castration-Resistant Prostate CancerNCT04662580
Prostate Cancer
ARX517
18 Years - Ambrx, Inc.
A Trial of CTT1403 for Metastatic Castration Resistant Prostate CancerNCT03822871
Prostate Cancer
CTT1403
CTT1057
68Ga-PSMA-11
18 Years - Cancer Targeted Technology
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation TherapyNCT05155046
Localized Prost...
18F-DCFPyL
18 Years - National Institutes of Health Clinical Center (CC)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: